Mammography Facility Adverse Event and Action Report - November 09, 2017: Riverwoods Advanced Diagnostic Imaging Center
As part of the Mammography Quality Standards Act (MQSA), Congress mandated there be annual reporting of adverse actions taken against mammography facilities. Congress stipulated that the report be made available to physicians and the general public and that it should include information that is useful in evaluating the performance of mammography facilities nationwide. In order to provide this information in the timeliest manner, we now post the following information in “real time,” as actions taken against mammography facilities are concluded:
Mammography Facility Against Which There Was An Adverse Action
The State of Utah
Facility Name and Address:
Riverwoods Advanced Diagnostic Imaging Center
3152 N University, Ste 100
Provo, UT 84604
Facility ID Number:
On June 20, 2017, the American College of Radiology (ACR) initiated a Full Additional Mammography Review (AMR) of mammograms performed by this facility based on deficiencies noted with the clinical images submitted by the facility during a Random Image Check, a clinical image review process required to be performed by accreditation bodies by the MQSA.
The ACR notified the facility on July 26, 2017 that the results of the AMR revealed that ten (10) out of thirty (30) clinical cases reviewed failed to meet the ACR’s clinical image evaluation criteria.
Based on the failed AMR results, on August 07, 2017, the ACR revoked the facility’s accreditation.
After evaluating the reasons for the accreditation revocation, on August 08, 2017, the Food and Drug Administration (FDA) declared the facility’s MQSA certificate to be no longer in effect until such time as the facility’s accreditation is reinstated and the facility has complied with all the requirements of the FDA.
Based on the serious image quality deficiencies noted during the AMR, the FDA declared the mammography performed at this facility to be a serious risk to human health and therefore required the facility to perform a Patient and Referring Healthcare Provider Notification (PPN) to alert all at-risk patients and their providers of the mammography quality problems at the facility.
The facility successfully completed the PPN and was notified of such by the FDA on October 17, 2017.
Status of the Facility:
The facility’s accreditation was reinstated and the facility was issued an MQSA certificate. The facility is currently performing mammography.